Day: January 6, 2023
Precision BioSciences Receives Favorable Type C Feedback from the FDA on the Company’s Chemistry, Manufacturing, and Controls (CMC) Strategies for Late-Stage Development of Azercabtagene Zapreleucel, its Lead Allogeneic CAR T Clinical Candidate
- FDA feedback signals the Company’s CMC plans shared are in alignment with Agency requirements and expectations - CMC regulatory feedback is a critical step in the pathway for development of azer-cel DURHAM, N.C. --(BUSINESS WIRE)--Jan. 6, 2023-- Precision BioSciences (Nasdaq: DTIL), a clinical